Skip to main content
Erschienen in: Surgery Today 3/2013

01.03.2013 | Review Article

Surgery for a gastroenteropancreatic neuroendocrine tumor (GEPNET) in multiple endocrine neoplasia type 1

verfasst von: Kazuhiro Hanazaki, Akihiro Sakurai, Masaya Munekage, Kengo Ichikawa, Tsutomu Namikawa, Takehiro Okabayashi, Masayuki Imamura

Erschienen in: Surgery Today | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominantly inherited endocrine tumor syndrome characterized by tumor development in various endocrine organs such as the parathyroid, endocrine pancreas, anterior pituitary and adrenal cortex. The first extensive database for Asian patients with MEN1 was established by the MEN Consortium of Japan. Although the clinical features of Japanese patients with MEN1 are similar to those from Western countries, there are several characteristic differences between them. In particular, gastroenteropancreatic neuroendocrine tumor (GEPNET) is seen in approximately 60 % of patients with MEN1 in Japan. Although its development is the strongest prognostic factor in patients with MEN1, the characteristics of MEN1-associated GEPNET still remain unclear. This is especially true for the differences in clinical features of GEPNET with and without MEN1. Improved long-term survival is obtained by curative surgery for patients with MEN1-associated GEPNET. The current surgical indications are expanding even in patients with hepatic metastases because of the improved surgical outcome. This article reviews the clinical characteristics in these patients with a particular focus on surgery, diagnosis, surgical indications, surgical method, and surgical outcome.
Literatur
1.
2.
Zurück zum Zitat Wermer P. Endocrine adenomatosis, peptic ulcer disease in a large kindred: inherited multiple tumors, mosaic pleiotropism in man. Am J Med. 1963;35:205–8.PubMedCrossRef Wermer P. Endocrine adenomatosis, peptic ulcer disease in a large kindred: inherited multiple tumors, mosaic pleiotropism in man. Am J Med. 1963;35:205–8.PubMedCrossRef
3.
Zurück zum Zitat Sakurai A, Suzuki S, Kosugi S, Okamoto T, Uchino S, Miya A, et al. Multiple endocrine neoplasia type 1 in Japan: establishment and analysis of multicenter database. Clin Endocrinol. 2012;76(4):533–9.CrossRef Sakurai A, Suzuki S, Kosugi S, Okamoto T, Uchino S, Miya A, et al. Multiple endocrine neoplasia type 1 in Japan: establishment and analysis of multicenter database. Clin Endocrinol. 2012;76(4):533–9.CrossRef
4.
Zurück zum Zitat Gibril F, Venzon DJ, Ojeburu JV, Bashir S, Jensen RT. Prospective study of the natural history of gastrinoma in patients with MEN1: definition of an aggressive and a nonaggressive form. J Clin Endocrinol Metab. 2001;86(11):5282–93.PubMedCrossRef Gibril F, Venzon DJ, Ojeburu JV, Bashir S, Jensen RT. Prospective study of the natural history of gastrinoma in patients with MEN1: definition of an aggressive and a nonaggressive form. J Clin Endocrinol Metab. 2001;86(11):5282–93.PubMedCrossRef
5.
Zurück zum Zitat Glascock JM, Carty SE. Multiple endocrine neoplasia type 1: fresh perspective on clinical features and penetrance. Surg Oncol. 2002;11:143–50.PubMedCrossRef Glascock JM, Carty SE. Multiple endocrine neoplasia type 1: fresh perspective on clinical features and penetrance. Surg Oncol. 2002;11:143–50.PubMedCrossRef
6.
Zurück zum Zitat Kimura W, Tezuka K, Hirai I. Surgical management of pancreatic neuroendocrine tumors. Surg Today. 2011;41(10):1332–43.PubMedCrossRef Kimura W, Tezuka K, Hirai I. Surgical management of pancreatic neuroendocrine tumors. Surg Today. 2011;41(10):1332–43.PubMedCrossRef
7.
Zurück zum Zitat Dickson PV, Rich TA, Xing Y, Cote GJ, Wang H, Perrier ND, et al. Achieving eugastrinemia in MEN1 patients: both duodenal inspection and formal lymph node dissection are important. Surgery. 2011;150:1143–52.PubMedCrossRef Dickson PV, Rich TA, Xing Y, Cote GJ, Wang H, Perrier ND, et al. Achieving eugastrinemia in MEN1 patients: both duodenal inspection and formal lymph node dissection are important. Surgery. 2011;150:1143–52.PubMedCrossRef
8.
Zurück zum Zitat Brandi ML, Gagel RF, Angeli A, Bilezkian JP, Beck-Peccoz P, Bordi C, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001;86:5658–71.PubMedCrossRef Brandi ML, Gagel RF, Angeli A, Bilezkian JP, Beck-Peccoz P, Bordi C, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001;86:5658–71.PubMedCrossRef
9.
Zurück zum Zitat Fraker DL, Norton JA, Alexander HR, Venzon DJ, Jensen RT. Surgery in Zollinger–Ellison syndrome alters the natural history of gastrinoma. Ann Surg. 1994;220:320–30.PubMedCrossRef Fraker DL, Norton JA, Alexander HR, Venzon DJ, Jensen RT. Surgery in Zollinger–Ellison syndrome alters the natural history of gastrinoma. Ann Surg. 1994;220:320–30.PubMedCrossRef
10.
Zurück zum Zitat Norton JA, Fraker DL, Alexander HR, Gibril F, Liewehr DJ, Venzon DJ, Jensen RT. Surgery increases survival in patients with gastrinoma. Ann Surg. 2006;244:410–9.PubMed Norton JA, Fraker DL, Alexander HR, Gibril F, Liewehr DJ, Venzon DJ, Jensen RT. Surgery increases survival in patients with gastrinoma. Ann Surg. 2006;244:410–9.PubMed
11.
Zurück zum Zitat Bartsch DK, Fendrich V, Langer P, Celik I, Kann PH, Rothmund M. Outcome of duodenopancreatic resections in patients with multiple endocrine neoplasia type 1. Ann Surg. 2005;242:757–66.PubMedCrossRef Bartsch DK, Fendrich V, Langer P, Celik I, Kann PH, Rothmund M. Outcome of duodenopancreatic resections in patients with multiple endocrine neoplasia type 1. Ann Surg. 2005;242:757–66.PubMedCrossRef
12.
Zurück zum Zitat Lévy-Bohbot N, Merle C, Goudet P, Delemer B, Calender A, Jolly D, et al. Prevalence, characteristics and prognosis of MEN1-associated glucagonomas, VIPomas, and somatostatinomas: study from the GTE (Groupe des Tumeurs Endocrines) registry. Gastroenterol Clin Biol. 2004;28(11):1075–81.PubMedCrossRef Lévy-Bohbot N, Merle C, Goudet P, Delemer B, Calender A, Jolly D, et al. Prevalence, characteristics and prognosis of MEN1-associated glucagonomas, VIPomas, and somatostatinomas: study from the GTE (Groupe des Tumeurs Endocrines) registry. Gastroenterol Clin Biol. 2004;28(11):1075–81.PubMedCrossRef
13.
Zurück zum Zitat Trump D, Farren B, Wooding C, Pang JT, Besser GM, Buchanan KD, et al. Clinical studies of multiple endocrine neoplasia type 1 (MEN1). Quart J Med. 1996;89(9):653–69.CrossRef Trump D, Farren B, Wooding C, Pang JT, Besser GM, Buchanan KD, et al. Clinical studies of multiple endocrine neoplasia type 1 (MEN1). Quart J Med. 1996;89(9):653–69.CrossRef
14.
Zurück zum Zitat Ito T, Sasano H, Tanaka M, Osamura RY, Sasaki I, Kimura W, et al. Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol. 2010;45:234–43.PubMedCrossRef Ito T, Sasano H, Tanaka M, Osamura RY, Sasaki I, Kimura W, et al. Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol. 2010;45:234–43.PubMedCrossRef
15.
Zurück zum Zitat Waldmann J, Bartsch DK, Kann PH, Fendrich V, Rothmund M, Langer P. Adrenal involvement in multiple endocrine neoplasia type 1: results of 7 years prospective screening. Langenbeck’s Arch Surg. 2007;392:437–43.CrossRef Waldmann J, Bartsch DK, Kann PH, Fendrich V, Rothmund M, Langer P. Adrenal involvement in multiple endocrine neoplasia type 1: results of 7 years prospective screening. Langenbeck’s Arch Surg. 2007;392:437–43.CrossRef
16.
Zurück zum Zitat Kann PH, Bittinger F, Engelbach M, Bohner S, Weis A, Beyer J. Endosonography of insulin-secreting and clinically non-functioning neuroendocrine tumors of the pancreas: criteria for benignancy and malignancy. Euro J Med Res. 2001;6:385–90. Kann PH, Bittinger F, Engelbach M, Bohner S, Weis A, Beyer J. Endosonography of insulin-secreting and clinically non-functioning neuroendocrine tumors of the pancreas: criteria for benignancy and malignancy. Euro J Med Res. 2001;6:385–90.
17.
Zurück zum Zitat Kann PH, Balakina E, Ivan D, Bartsch DK, Meyer S, Klose KJ, Behr T, Langer P. Natural course of small, asymptomatic neuroendocrine pancreatic tumours in multiple endocrine neoplasia type 1: an endoscopic ultrasound imaging study. Endocr Relat Cancer. 2006;13:1195–202.PubMedCrossRef Kann PH, Balakina E, Ivan D, Bartsch DK, Meyer S, Klose KJ, Behr T, Langer P. Natural course of small, asymptomatic neuroendocrine pancreatic tumours in multiple endocrine neoplasia type 1: an endoscopic ultrasound imaging study. Endocr Relat Cancer. 2006;13:1195–202.PubMedCrossRef
18.
Zurück zum Zitat Schaefer S, Shipotko M, Meyer S, Ivan D, Klose KJ, Waldmann J, Langer P, Kann PH. Natural course of small adrenal lesions in multiple endocrine neoplasia type 1: an endoscopic ultrasound imaging study. Euro J Endocrinol. 2008;158:699–704.CrossRef Schaefer S, Shipotko M, Meyer S, Ivan D, Klose KJ, Waldmann J, Langer P, Kann PH. Natural course of small adrenal lesions in multiple endocrine neoplasia type 1: an endoscopic ultrasound imaging study. Euro J Endocrinol. 2008;158:699–704.CrossRef
19.
Zurück zum Zitat Imamura M, Takahashi K, Adachi H, Minematsu S, Shimada Y, Naito M, Suzuki T, Tobe T, Azuma T. Usefulness of selective arterial secretin injection test for localization of gastrinoma in the Zollinger–Ellison syndrome. Ann Surg. 1987;205:230–9.PubMedCrossRef Imamura M, Takahashi K, Adachi H, Minematsu S, Shimada Y, Naito M, Suzuki T, Tobe T, Azuma T. Usefulness of selective arterial secretin injection test for localization of gastrinoma in the Zollinger–Ellison syndrome. Ann Surg. 1987;205:230–9.PubMedCrossRef
20.
Zurück zum Zitat Imamura M, Takahashi K, Isobe Y, Hattori Y, Satomura K, Tobe T. Curative resection of multiple gastrinoma aided by selective arterial injection test and intraoperative secretin test. Ann Surg. 1989;210:710–8.PubMedCrossRef Imamura M, Takahashi K, Isobe Y, Hattori Y, Satomura K, Tobe T. Curative resection of multiple gastrinoma aided by selective arterial injection test and intraoperative secretin test. Ann Surg. 1989;210:710–8.PubMedCrossRef
21.
Zurück zum Zitat Imamura M, Komoto I, Ota S, Hiratsuka T, Kosugi S, Doi R, Awane M, Inoue N. Biochemically curative surgery for gastrinoma in multiple endocrine neoplasia type 1 patient. World J Gastroenterol. 2011;17:1343–53.PubMedCrossRef Imamura M, Komoto I, Ota S, Hiratsuka T, Kosugi S, Doi R, Awane M, Inoue N. Biochemically curative surgery for gastrinoma in multiple endocrine neoplasia type 1 patient. World J Gastroenterol. 2011;17:1343–53.PubMedCrossRef
22.
Zurück zum Zitat Imamura M, Komoto I. Gastrinoma. In: Hubbard J, Inabnet WB, Lo CY, editors. Endocrine surgery: principles and practice (Springer specialist surgery series). London: Springer; 2009. p. 507–21. Imamura M, Komoto I. Gastrinoma. In: Hubbard J, Inabnet WB, Lo CY, editors. Endocrine surgery: principles and practice (Springer specialist surgery series). London: Springer; 2009. p. 507–21.
23.
Zurück zum Zitat Makuuchi M, Hasegawa H, Yamazaki S. Intraoperative ultrasonic examination for hepatectomy. Ultrasound Med Biol. 1983;Suppl 2:493–7.PubMed Makuuchi M, Hasegawa H, Yamazaki S. Intraoperative ultrasonic examination for hepatectomy. Ultrasound Med Biol. 1983;Suppl 2:493–7.PubMed
24.
Zurück zum Zitat Zhang K, Kokudo N, Hasegawa K, Arita J, Tang W, Aoki T, et al. Detection of new tumors by intraoperative ultrasonography during repeated hepatic resections for hepatocellular carcinoma. Arch Surg. 2007;142(12):1170–5.PubMedCrossRef Zhang K, Kokudo N, Hasegawa K, Arita J, Tang W, Aoki T, et al. Detection of new tumors by intraoperative ultrasonography during repeated hepatic resections for hepatocellular carcinoma. Arch Surg. 2007;142(12):1170–5.PubMedCrossRef
25.
Zurück zum Zitat Kouvaraki MA, Shapiro SE, Cote GJ, Lee JE, Yao JC, Waguespack SG, et al. Management of pancreatic endocrine tumors in multiple endocrine neoplasia type 1. World J Surg. 2006;30:643–53.PubMedCrossRef Kouvaraki MA, Shapiro SE, Cote GJ, Lee JE, Yao JC, Waguespack SG, et al. Management of pancreatic endocrine tumors in multiple endocrine neoplasia type 1. World J Surg. 2006;30:643–53.PubMedCrossRef
26.
Zurück zum Zitat Norton JA, Fang TD, Jensen RT. Surgery for gastrinoma and insulinoma in multiple endocrine neoplasia type 1. J Natl Compr Canc Netw. 2006;4(2):148–53.PubMed Norton JA, Fang TD, Jensen RT. Surgery for gastrinoma and insulinoma in multiple endocrine neoplasia type 1. J Natl Compr Canc Netw. 2006;4(2):148–53.PubMed
27.
Zurück zum Zitat Plökinger U, Rindi G, Arnold R, Eriksson B, Krenning EP, de Herder WW, et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumors: a consensus statement of behalf of the European Neuroendocrine Tumor Society (ENETS). Neuroendocrinology. 2004;80(6):394–424.CrossRef Plökinger U, Rindi G, Arnold R, Eriksson B, Krenning EP, de Herder WW, et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumors: a consensus statement of behalf of the European Neuroendocrine Tumor Society (ENETS). Neuroendocrinology. 2004;80(6):394–424.CrossRef
28.
Zurück zum Zitat Thompson NW. Current concepts in the surgical management of multiple endocrine neoplasia type 1 pancreatic-duodenal disease: results in the treatment of 40 patients with Zollinger–Ellison syndrome, hypoglycemia or both. J Intern Med. 1998;243:495–500.PubMedCrossRef Thompson NW. Current concepts in the surgical management of multiple endocrine neoplasia type 1 pancreatic-duodenal disease: results in the treatment of 40 patients with Zollinger–Ellison syndrome, hypoglycemia or both. J Intern Med. 1998;243:495–500.PubMedCrossRef
29.
Zurück zum Zitat Imamura M. Changing clinical practice for NET. Igaku no Ayumi. 2008;224(10):753–6. (in Japanese). Imamura M. Changing clinical practice for NET. Igaku no Ayumi. 2008;224(10):753–6. (in Japanese).
30.
Zurück zum Zitat Steinmüller T, Kianmanesh R, Falconi M, Scarpa A, Taal B, Kwekkeboom DJ, et al. Consensus guidelines for the management of patients with liver metastases from digestive (neuro) endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2008;87:47–62.PubMedCrossRef Steinmüller T, Kianmanesh R, Falconi M, Scarpa A, Taal B, Kwekkeboom DJ, et al. Consensus guidelines for the management of patients with liver metastases from digestive (neuro) endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2008;87:47–62.PubMedCrossRef
31.
Zurück zum Zitat Touzios JG, Kiely JM, Pitt SC, Rilling WS, Quebbeman EJ, Wilson SD, et al. Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg. 2005;241:776–83.PubMedCrossRef Touzios JG, Kiely JM, Pitt SC, Rilling WS, Quebbeman EJ, Wilson SD, et al. Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg. 2005;241:776–83.PubMedCrossRef
32.
Zurück zum Zitat Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg. 2003;197:29–37.PubMedCrossRef Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg. 2003;197:29–37.PubMedCrossRef
33.
Zurück zum Zitat Scigliano S, Lebtahi R, Maire F, Stievenart JL, Kianmnesh R, Sauvanet A, et al. Clinical and imaging follow-up after exhaustive liver resection of endocrine metastases: a 15-year monocentric experience. Endocr Relat Cancer. 2009;16:977–90.PubMedCrossRef Scigliano S, Lebtahi R, Maire F, Stievenart JL, Kianmnesh R, Sauvanet A, et al. Clinical and imaging follow-up after exhaustive liver resection of endocrine metastases: a 15-year monocentric experience. Endocr Relat Cancer. 2009;16:977–90.PubMedCrossRef
34.
Zurück zum Zitat Mayo SC, de Jong MC, Pulitano C, Clary BM, Reddy SK, Gamblin TC, et al. Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol. 2010;17:3129–36.PubMedCrossRef Mayo SC, de Jong MC, Pulitano C, Clary BM, Reddy SK, Gamblin TC, et al. Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol. 2010;17:3129–36.PubMedCrossRef
35.
Zurück zum Zitat Ellison EC, Sparks J, Verducci JS, Johnson JA, Muscarella P, Bloomston M, et al. 50-year appraisal of gastrinoma: recommendations for staging and treatment. J Am Coll Surg. 2006;202(6):897–905.PubMedCrossRef Ellison EC, Sparks J, Verducci JS, Johnson JA, Muscarella P, Bloomston M, et al. 50-year appraisal of gastrinoma: recommendations for staging and treatment. J Am Coll Surg. 2006;202(6):897–905.PubMedCrossRef
36.
Zurück zum Zitat Imamura M, Komoto I, Doi R, Onodera H, Kobayashi H, Kawai Y. New pancreas-preserving total duodenectomy technique. World J Surg. 2005;29:203–7.PubMedCrossRef Imamura M, Komoto I, Doi R, Onodera H, Kobayashi H, Kawai Y. New pancreas-preserving total duodenectomy technique. World J Surg. 2005;29:203–7.PubMedCrossRef
37.
Zurück zum Zitat Lopez CL, Waldmann J, Fendrich V, Langer P, Kann PH, Bratsch DK. Long-term results of surgery for pancreatic neuroendocrine neoplasms in patients with MEN1. Langenbecks Arch Surg. 2011 [Epub ahead of print]. Lopez CL, Waldmann J, Fendrich V, Langer P, Kann PH, Bratsch DK. Long-term results of surgery for pancreatic neuroendocrine neoplasms in patients with MEN1. Langenbecks Arch Surg. 2011 [Epub ahead of print].
38.
Zurück zum Zitat Maeda H, Hanazaki K. Pancreatogenic diabetes after pancreatic resection. Pancreatology. 2011;11:268–76.PubMedCrossRef Maeda H, Hanazaki K. Pancreatogenic diabetes after pancreatic resection. Pancreatology. 2011;11:268–76.PubMedCrossRef
39.
Zurück zum Zitat Jethwa P, Sodergren M, Lala A, Webber J, Buckels JA, Bramhall SR, Mirza DF. Diabetic control after total pancreatectomy. Dig Liver Dis. 2006;38:415–9.PubMedCrossRef Jethwa P, Sodergren M, Lala A, Webber J, Buckels JA, Bramhall SR, Mirza DF. Diabetic control after total pancreatectomy. Dig Liver Dis. 2006;38:415–9.PubMedCrossRef
40.
Zurück zum Zitat Kono T, Hanazaki K, Yazawa K, Ashizawa S, Fisher WE, Wang XP, et al. Pancreatic polypeptide administration reduces insulin requirements of artificial pancreas in pancreatectomized dogs. Artif Organs. 2005;29:83–7.PubMedCrossRef Kono T, Hanazaki K, Yazawa K, Ashizawa S, Fisher WE, Wang XP, et al. Pancreatic polypeptide administration reduces insulin requirements of artificial pancreas in pancreatectomized dogs. Artif Organs. 2005;29:83–7.PubMedCrossRef
41.
Zurück zum Zitat Okabayashi T, Nishimori I, Maeda H, Yamashita K, Yatabe T, Kohsaki T, et al. Continuous postoperative blood glucose monitoring and control by artificial pancreas in patients having pancreatic resection: a prospective randomized clinical trial. Arch Surg. 2009;144:933–7.PubMedCrossRef Okabayashi T, Nishimori I, Maeda H, Yamashita K, Yatabe T, Kohsaki T, et al. Continuous postoperative blood glucose monitoring and control by artificial pancreas in patients having pancreatic resection: a prospective randomized clinical trial. Arch Surg. 2009;144:933–7.PubMedCrossRef
42.
Zurück zum Zitat Hanazaki K, Okabayashi T, Maeda H. Tight glycemic control using an artificial pancreas to control perioperative hyperglycemia decreases surgical site infection in pancreatectomized or hepatectomized patients. Ann Surg. 2009;250:351–2.CrossRef Hanazaki K, Okabayashi T, Maeda H. Tight glycemic control using an artificial pancreas to control perioperative hyperglycemia decreases surgical site infection in pancreatectomized or hepatectomized patients. Ann Surg. 2009;250:351–2.CrossRef
43.
Zurück zum Zitat Hanazaki K, Maeda H, Okabayashi T. Relationship between perioperative glycemic control and postoperative infections. World J Gastroenterol. 2009;15:4122–5.PubMedCrossRef Hanazaki K, Maeda H, Okabayashi T. Relationship between perioperative glycemic control and postoperative infections. World J Gastroenterol. 2009;15:4122–5.PubMedCrossRef
44.
Zurück zum Zitat Hanazaki K, Maeda H, Okabayashi T. Tight perioperative glycemic control using an artificial endocrine pancreas. Surg Today. 2010;40(1):1–7.PubMedCrossRef Hanazaki K, Maeda H, Okabayashi T. Tight perioperative glycemic control using an artificial endocrine pancreas. Surg Today. 2010;40(1):1–7.PubMedCrossRef
45.
Zurück zum Zitat Kianmanesh R, Sauvanet A, Hentic O, Couvelard A, Lévy P, Vilgrain V, et al. Two-step surgery for synchronous bilobar liver metastases from digestive endocrine tumors: a safe approach for radical resection. Ann Surg. 2008;247:659–65.PubMedCrossRef Kianmanesh R, Sauvanet A, Hentic O, Couvelard A, Lévy P, Vilgrain V, et al. Two-step surgery for synchronous bilobar liver metastases from digestive endocrine tumors: a safe approach for radical resection. Ann Surg. 2008;247:659–65.PubMedCrossRef
46.
Zurück zum Zitat Bechstein WO, Neuhaus P. Liver transplantation for hepatic metastases of neuroendocrine tumors. Ann N Y Acad Sci. 1994;733:507–14.PubMedCrossRef Bechstein WO, Neuhaus P. Liver transplantation for hepatic metastases of neuroendocrine tumors. Ann N Y Acad Sci. 1994;733:507–14.PubMedCrossRef
47.
Zurück zum Zitat Lehnert T. Liver transplantation for metastatic neuroendocrine carcinoma: an analysis of 103 patients. Transplantation. 1998;66:1307–12.PubMedCrossRef Lehnert T. Liver transplantation for metastatic neuroendocrine carcinoma: an analysis of 103 patients. Transplantation. 1998;66:1307–12.PubMedCrossRef
48.
Zurück zum Zitat Ahlman H, Friman S, Cahlin C, Nilsson O, Jansson S, Wängberg B, et al. Liver transplantation for treatment of metastatic neuroendocrine tumors. Ann N Y Acad Sci. 2004;1014:265–9.PubMedCrossRef Ahlman H, Friman S, Cahlin C, Nilsson O, Jansson S, Wängberg B, et al. Liver transplantation for treatment of metastatic neuroendocrine tumors. Ann N Y Acad Sci. 2004;1014:265–9.PubMedCrossRef
49.
Zurück zum Zitat van Vilsteren FG, Baskin-Bey ES, Nagorney DM, Sanderson SO, Kremers WK, Rosen CB, et al. Liver transplantation for gastroenteropancreatic neuroendocrine cancers: defining selection criteria to improve survival. Liver Transpl. 2006;12:448–56.PubMedCrossRef van Vilsteren FG, Baskin-Bey ES, Nagorney DM, Sanderson SO, Kremers WK, Rosen CB, et al. Liver transplantation for gastroenteropancreatic neuroendocrine cancers: defining selection criteria to improve survival. Liver Transpl. 2006;12:448–56.PubMedCrossRef
50.
Zurück zum Zitat Olausson M, Friman S, Herlenius G, Cahlin C, Nilsson O, Jansson S, et al. Orthotopic liver or multivisceral transplantation as treatment of metastatic neuroendocrine tumors. Liver Transpl. 2007;13:327–33.PubMedCrossRef Olausson M, Friman S, Herlenius G, Cahlin C, Nilsson O, Jansson S, et al. Orthotopic liver or multivisceral transplantation as treatment of metastatic neuroendocrine tumors. Liver Transpl. 2007;13:327–33.PubMedCrossRef
51.
Zurück zum Zitat Mathe Z, Tagkalos E, Paul A, Molmenti EP, Kobori L, Fouzas I, et al. Liver transplantation for hepatic metastases of neuroendocrine pancreatic tumors: a survival based analysis. Transplantation. 2011;91(5):575–82.PubMedCrossRef Mathe Z, Tagkalos E, Paul A, Molmenti EP, Kobori L, Fouzas I, et al. Liver transplantation for hepatic metastases of neuroendocrine pancreatic tumors: a survival based analysis. Transplantation. 2011;91(5):575–82.PubMedCrossRef
52.
Zurück zum Zitat Kulke MH, Anthony LB, Bushnell DL, de Herder WW, Goldsmith SJ, Klimstra DS, et al. NANTES treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas. 2010;39(6):735–52.PubMedCrossRef Kulke MH, Anthony LB, Bushnell DL, de Herder WW, Goldsmith SJ, Klimstra DS, et al. NANTES treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas. 2010;39(6):735–52.PubMedCrossRef
53.
Zurück zum Zitat Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology. 2008;135(5):1469–92.PubMedCrossRef Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology. 2008;135(5):1469–92.PubMedCrossRef
54.
Zurück zum Zitat Osborne DA, Zervos EE, Strosberg J, Boe BA, Malafa M, Rosemurgy AS, et al. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol. 2006;13(4):572–81.PubMedCrossRef Osborne DA, Zervos EE, Strosberg J, Boe BA, Malafa M, Rosemurgy AS, et al. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol. 2006;13(4):572–81.PubMedCrossRef
Metadaten
Titel
Surgery for a gastroenteropancreatic neuroendocrine tumor (GEPNET) in multiple endocrine neoplasia type 1
verfasst von
Kazuhiro Hanazaki
Akihiro Sakurai
Masaya Munekage
Kengo Ichikawa
Tsutomu Namikawa
Takehiro Okabayashi
Masayuki Imamura
Publikationsdatum
01.03.2013
Verlag
Springer Japan
Erschienen in
Surgery Today / Ausgabe 3/2013
Print ISSN: 0941-1291
Elektronische ISSN: 1436-2813
DOI
https://doi.org/10.1007/s00595-012-0376-5

Weitere Artikel der Ausgabe 3/2013

Surgery Today 3/2013 Zur Ausgabe

Leitlinien kompakt für die Allgemeinmedizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Facharzt-Training Allgemeinmedizin

Die ideale Vorbereitung zur anstehenden Prüfung mit den ersten 49 von 100 klinischen Fallbeispielen verschiedener Themenfelder

Mehr erfahren

Bei Herzinsuffizienz muss „Eisenmangel“ neu definiert werden

16.05.2024 Herzinsuffizienz Nachrichten

Bei chronischer Herzinsuffizienz macht es einem internationalen Expertenteam zufolge wenig Sinn, die Diagnose „Eisenmangel“ am Serumferritin festzumachen. Das Team schlägt vor, sich lieber an die Transferrinsättigung zu halten.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Diabetestechnologie für alle?

15.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Eine verbesserte Stoffwechseleinstellung und höhere Lebensqualität – Diabetestechnologien sollen den Alltag der Patienten erleichtern. Dass CGM, AID & Co. bei Typ-1-Diabetes helfen, ist belegt. Bei Typ-2 gestaltet sich die Sache komplizierter.

Update Allgemeinmedizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.